Katherine Stueland, Chief Executive Officer at GeneDx Holdings Corp. (WGS), sold 84,840 shares at $90.13 ($7.6M) on 2025-04-09, disclosed to the SEC on 2025-04-10.
Scheduled sale ($7.6M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $81.16 | 2,024 | $164K | 2.2% |
| 2 | $81.16 | 2,024 | $164K | 2.2% |
| 3 | $82.17 | 3,134 | $258K | 3.4% |
| 4 | $82.17 | 3,134 | $258K | 3.4% |
| 5 | $83.25 | 3,297 | $274K | 3.6% |
| 6 | $83.25 | 3,297 |
| $274K |
| 3.6% |
| 7 | $84.28 | 2,745 | $231K | 3.0% |
| 8 | $84.28 | 2,745 | $231K | 3.0% |
| 9 | $85.44 | 3,175 | $271K | 3.6% |
| 10 | $86.34 | 5,855 | $506K | 6.6% |
| 11 | $86.34 | 5,855 | $506K | 6.6% |
| 12 | $87.30 | 373 | $33K | 0.4% |
| 13 | $88.70 | 300 | $27K | 0.3% |
| 14 | $90.13 | 1,600 | $144K | 1.9% |
| 15 | $91.27 | 1,900 | $173K | 2.3% |
| 16 | $92.28 | 1,000 | $92K | 1.2% |
| 17 | $93.33 | 9,628 | $899K | 11.8% |
| 18 | $93.33 | 9,628 | $899K | 11.8% |
| 19 | $94.55 | 4,511 | $427K | 5.6% |
| 20 | $94.55 | 4,511 | $427K | 5.6% |
| 21 | $95.51 | 3,173 | $303K | 4.0% |
| 22 | $95.51 | 3,173 | $303K | 4.0% |
| 23 | $96.29 | 3,174 | $306K | 4.0% |
| 24 | $96.29 | 3,174 | $306K | 4.0% |
| 25 | $97.24 | 705 | $69K | 0.9% |
| 26 | $97.24 | 705 | $69K | 0.9% |
| Total | $89.71 avg | 84,840 | $7.6M | 100% |
| Filing → |
| WGS | SELL | 2026-06-18 | $638K | — | Filing → |
| WGS | SELL | 2026-06-11 | $196K | — | Filing → |
| WGS | SELL | 2026-05-01 | $142K | — | Filing → |